Contineum Therapeutics, Inc. - Common stock (CTNM)
CTNM moved a median of 0.00% 30 minutes after news, and +0.24% by the close. How CTNM actually reacts to news — the realized, point-in-time move the market made, measured across 225 labeled events over the last three years with zero look-ahead.
CTNM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 205 |
| 30-min | 0.00% | 45% | 214 |
| 60-min | -0.28% | 46% | 224 |
| to close | +0.24% | 54% | 223 |
| Middle 50% of CTNM reactions | -1.24% to +1.44% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 225 |
Half of all Contineum Therapeutics, Inc. - Common stock news events land between -1.24% and +1.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CTNM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 22 | +1.61% | 64% | +0.32% |
| Rating reiterations | 19 | +0.06% | 53% | +2.52% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how CTNM ranks against every other measured name →
That’s how CTNM usually reacts — get an email when it moves on news →Email me when CTNM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CTNM's baseline. Nothing else.
Recent CTNM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Contineum Therapeutics, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | -6.15% | |
| Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder | Press release | Business Wire | +0.84% | +0.44% | |
| Form 8-K Contineum Therapeutics, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.84% | +0.44% | |
| Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference | Press release | Business Wire | +0.00% | +0.24% | |
| Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones | Press release | Business Wire | +0.79% | -1.65% | |
| Form 10-Q Contineum Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | -1.65% | |
| Form 8-K Contineum Therapeutics, For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -1.65% | |
| Form 8-K Contineum Therapeutics, For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.87% | |
| Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry | Press release | Business Wire | +0.12% | -6.90% | |
| Form 8-K Contineum Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -2.76% | +6.16% | |
| Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference | Press release | Business Wire | -0.34% | -4.99% | |
| Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.30% | -4.39% | |
| Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference | Press release | Business Wire | +0.00% | +3.59% | |
| Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference | Press release | Business Wire | +0.00% | +0.52% | |
| Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones | Press release | Business Wire | -0.55% | +3.11% | |
| Form 10-Q Contineum Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.55% | +3.11% | |
| Form 8-K Contineum Therapeutics, For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | +3.11% | |
| Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.30% | +7.20% | |
| Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain | Press release | Business Wire | -2.19% | -0.08% | |
| Form 8-K Contineum Therapeutics, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -2.19% | -0.08% | |
| Form ARS Contineum Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.19% | -0.08% | |
| Form DEF 14A Contineum Therapeutics, For: Jun 26 | SEC filing · Form DEF | SEC EDGAR | -2.19% | -0.08% | |
| Form DEFA14A Contineum Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -2.19% | -0.08% | |
| Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.00% | — | |
| Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones | Press release | Business Wire | -4.62% | -5.64% | |
| Form 10-K Contineum Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.62% | -5.64% | |
| Form 8-K Contineum Therapeutics, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -4.62% | -5.64% | |
| Form S-8 Contineum Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -4.62% | -5.64% | |
| Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference | Press release | Business Wire | -0.28% | +4.57% | |
| Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -2.10% | +4.78% | |
| Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.87% | +2.10% | |
| Form 8-K Contineum Therapeutics, For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +8.89% | |
| Form 8-K Contineum Therapeutics, For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +1.78% | +0.26% | |
| Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering | Press release | Business Wire | +0.81% | -5.68% | |
| Contineum Therapeutics Announces Proposed $75.0 Million Public Offering | Press release | Business Wire | +0.81% | -5.68% | |
| Form 8-K Contineum Therapeutics, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -5.68% | |
| Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference | Press release | Business Wire | +6.37% | +4.08% | |
| Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) | Press release | Business Wire | +2.00% | -0.23% | |
| Form 8-K Contineum Therapeutics, For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +2.00% | -0.23% | |
| Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones | Press release | Business Wire | +0.38% | +3.58% | |
| Form 10-Q Contineum Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.38% | +3.58% | |
| Form 8-K Contineum Therapeutics, For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | +3.58% | |
| Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 | Press release | Business Wire | -0.89% | +0.24% | |
| Form 8-K Contineum Therapeutics, For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +0.24% | |
| Contineum Therapeutics to Present at September Investor Conferences | Press release | Business Wire | -0.79% | +3.16% | |
| Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones | Press release | Business Wire | -2.91% | +2.43% | |
| Form 10-Q Contineum Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.91% | +2.43% | |
| Form 8-K Contineum Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -2.91% | +2.43% | |
| Form 8-K Contineum Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +1.25% | +2.75% | |
| Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 | Press release | Business Wire | -5.43% | +13.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CTNM section they belong to.
Where else CTNM is measured.
CTNM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Contineum Therapeutics, Inc. - Common stock's median reaction calculated?
Every labeled CTNM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 225 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of CTNM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CTNM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.